Related Experiment Video

Updated: May 18, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Telmisartan inhibits human urological cancer cell growth through early apoptosis

Masahide Matsuyama1, Kiyoaki Funao, Katsuyuki Kuratsukuri

  • 1Department of Transplantation and Clinical Immunology, Claude Bernard University of Lyon and Lyon Hospitals, Lyon, France ;

Experimental and Therapeutic Medicine
|September 21, 2012
PubMed

Insights

Telmisartan, an angiotensin II receptor blocker (ARB), significantly inhibits urological cancer cell growth and induces apoptosis. Other ARBs did not show similar anti-cancer effects, highlighting telmisartan

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Angiotensin II receptor blockers (ARBs) are established antihypertensive drugs.
  • Emerging evidence suggests ARBs may possess anti-cancer properties.
  • Telmisartan, an ARB, is known to activate peroxisome proliferator-activated receptor (PPAR)-γ.

Purpose of the Study:

  • To investigate the anti-proliferative effects of telmisartan and other ARBs on human urological cancer cell lines.
  • To determine if telmisartan's anti-cancer activity is mediated through PPAR-γ.
  • To evaluate telmisartan as a potential therapeutic agent for urological cancers.

Main Methods:

  • MTT assay to assess cell proliferation inhibition.
  • Flow cytometry and Hoechst staining to detect apoptosis and DNA fragmentation.
  • Testing of telmisartan, candesartan, valsartan, irbesartan, and losartan on renal cell carcinoma, bladder cancer, prostate cancer, and testicular cancer cell lines.

Main Results:

  • Telmisartan demonstrated significant, dose- and time-dependent inhibition of urological cancer cell proliferation.
  • Treatment with telmisartan induced early apoptosis and DNA fragmentation in cancer cells.
  • Other tested ARBs (candesartan, valsartan, irbesartan, losartan) did not affect urological cancer cell growth.

Conclusions:

  • Telmisartan exhibits potent anti-proliferative effects on human urological cancer cells, likely via PPAR-γ activation.
  • Telmisartan represents a promising candidate for the prevention and treatment of urological cancers.
  • Selective anti-cancer activity of telmisartan distinguishes it from other ARBs.

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...